News

Deal Announcements

Trius Therapeutics Completes $30 Million Series B

Tuesday, March 25, 2008 5:17:00 AM PDT | VentureDeal Staff
SAN DIEGO, CA -- Pharmaceutical company Trius Therapeutics has announced the closing of its second round of venture capital funding, receiving $30 million.

Trius is developing anti-bacterial drugs for the treatment of life-threatening infections.  The company's lead candidate, TR-701, is an oral and IV oxazolidinone antibiotic designed to treat Gram positive bacterial pathogens.

Kleiner Perkins Caufield & Byers led the round, which included previous investors InterWest Partners, Versant Ventures and Prism VentureWorks.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1